Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Recruiting now Phase 4 NCT05803941
Run by Novartis Pharmaceuticals · for 18 to 100 · Men
What this study is about
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Who can join (things the study team will check)
✅ You may be able to join if…
- Signed informed consent must be obtained prior to participation in the study
- Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.
🚫 You may not be able to join if…
- Inability to complete the needed investigational examinations due to any reason.
Where this trial is running
- Mayo Clinic Arizona, Scottsdale, Arizona, United States
- St. Joseph Hospital, Orange, California, United States
- Providence Saint Johns Health Ctr, Santa Monica, California, United States
- University of Colorado, Aurora, Colorado, United States
- Hartford Hospital, Hartford, Connecticut, United States
- VA Medical Center, Washington D.C., District of Columbia, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- University Cancer and Blood Center LLC, Athens, Georgia, United States
- Parkview Research Center, Fort Wayne, Indiana, United States
- Tulane Cancer Center, New Orleans, Louisiana, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Corewell Health William Beaum Hosp, Royal Oak, Michigan, United States
+ 42 more sites.
Who to contact
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05803941.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.